Track Galecto, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Galecto, Inc. DMRA · Stock Open Galecto, Inc. in new tab

21.60 USD
P/E
12.63
EPS
1.71
P/B
3.66
ROE
-115.80
Beta
1.51
Target Price
46.78 USD
Loading chart...
Key Metrics
Earnings dateMarch 18, 2027
P/E12.63
EPS1.71
Book Value5.91
Price to Book3.66
Debt/Equity0.22
% Insiders10.156%
Estimates
Forward P/E-9.89
Forward EPS-2.19
Target Mean Price46.78

DCF valuation

Model fair value for Galecto, Inc. (DMRA)
Result
Sign in to run the valuation for DMRA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Strong buy · mean target 46.78 USD (low 40.00, high 59.00) · as of 15 Nov 2026
Low 40.00
Mean 46.78
High 59.00
Price 21.60
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Galecto, Inc. Logo Galecto, Inc. Analysis (DMRA)

US Healthcare Official Website Stock

Is Galecto, Inc. a good investment? Galecto, Inc. (DMRA) is currently trading at 21.60 USD. Market analysts have a consensus price target of 46.78 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 12.63. This relatively low multiple may signal that Galecto, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Galecto, Inc. is expected to release its next earnings report on March 18, 2027. The market consensus estimate for Forward EPS is -2.19.

Investor FAQ

Does Galecto, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Galecto, Inc.?

Galecto, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 18, 2027. The company currently has a trailing EPS of 1.71.

Company Profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NASDAQ DMRA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 30, 2024 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion